Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy
Assessment of Quality of Life and the Toxicity of Chemotherapy in Patients With Malignancies in Clinical Stages III and IV Under Palliative Treatment With Chemotherapy or Hormone Therapy With or Without Nutritional Supplement TK3
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Sao Paulo
-
Avaré, Sao Paulo, Brazil, 18705000
- Recruiting
- Sana Casa de Avaré
-
Contact:
- Nilson Bruno Evangelista, Doctor
- Phone Number: +551437119100
- Email: smaadm@bol.com.br
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient Consent: Informed Consent and informed consent signed and dated by the patient (or his legal representative) and the professional who has obtained the consent. Must be delivered before inclusion. This term must be read and explained to the patient.
- Patients female or male, regardless of race or color.Able to ingest oral medication.
- Patients 30-80 years, with malignancy, clinical stage III or IV on chemo or hormone therapy.
- Patients who have a Karnofsky level between 60 and 80.
Exclusion Criteria:
- no agreement to sign the Deed of Consent.
- Need for use of parenteral nutrition.
- The need for food supplement already approved.
- Inability to receive the drug orally.
- Participation in another clinical trial involving chemotherapy drugs.
- Women being sexually active, which does not agree to adhere to the contraceptive methods adopted.
- Women lactating
- Any problem or condition that the investigator in the trial could be harmful to the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Experimental: TK3
1 capsule, 3 times per day.
|
Tritofano 160mg / Timina140mg and starch 150 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of Quality of Life
Time Frame: 0 day
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
0 day
|
|
Assessment of Quality of Life
Time Frame: 30 days
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
30 days
|
|
Assessment of Quality of Life
Time Frame: 60 days
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
60 days
|
|
Assessment of Quality of Life
Time Frame: 90 days
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
90 days
|
|
Assessment of Quality of Life
Time Frame: 120 days
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
120 days
|
|
Assessment of Quality of Life
Time Frame: 150 days
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
150 days
|
|
Assessment of Quality of Life
Time Frame: 180 days
|
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
|
180 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance status
Time Frame: 0 day
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
0 day
|
|
Perfomance status
Time Frame: 30 days
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
30 days
|
|
Performance Status
Time Frame: 60 days
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
60 days
|
|
Performance Status
Time Frame: 90 days
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
90 days
|
|
Performance Status
Time Frame: 120 days
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
120 days
|
|
Performance Status
Time Frame: 150 days
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
150 days
|
|
Performance Status
Time Frame: 180 days
|
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
|
180 days
|
|
Tumor Markers
Time Frame: 0 day
|
Analysis of tumor markers specific to each tumor
|
0 day
|
|
Tumor Markers
Time Frame: 30 day
|
Analysis of tumor markers specific to each tumor
|
30 day
|
|
Tumor Markers
Time Frame: 60 day
|
Analysis of tumor markers specific to each tumor
|
60 day
|
|
Tumor Markers
Time Frame: 90 day
|
Analysis of tumor markers specific to each tumor
|
90 day
|
|
Tumor Markers
Time Frame: 120 day
|
Analysis of tumor markers specific to each tumor
|
120 day
|
|
Tumor Markers
Time Frame: 150 day
|
Analysis of tumor markers specific to each tumor
|
150 day
|
|
Tumor Markers
Time Frame: 180 day
|
Analysis of tumor markers specific to each tumor
|
180 day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nilson Bruno Evangelista, Doctor, Lavilabor Natural Products Ltd
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TK3a_FIII_Janeiro/2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.